SEC Form 4 · accession 0001140361-15-037184

PDS Biotechnology Corp · PDSB

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Scientific Officer · Director

Period of report

Oct 6, 2015

Accepted (ET)

Oct 8, 2015 · 4:14 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001472091

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Oct 6, 2015	C	18,274	—	A	566,480	D
Common Stock^F1	Oct 6, 2015	C	3,928	—	A	570,408	D
Common Stock	Oct 6, 2015	J	194	$7.90	A	570,602	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series A Convertible Preferred Stock^F1	—	Oct 6, 2015	C	25,000	D	—	—	Common Stock	18,274	0	D
Series C-1 Convertible Preferred Stock^F1	—	Oct 6, 2015	C	5,373	D	—	—	Common Stock	3,928	0	D

F1The convertible preferred stock converted into the Issuer's common stock at a conversion ratio, as adjusted to give effect to the Issuer's 1-for-1.3681 reverse stock split effected on September 21, 2015, of one share of common stock for every 1.3681 shares of preferred stock immediately prior to the closing of the Issuer's initial public offering of common stock, and had no expiration date.
F2The Reporting Person received a total of 194 shares of the Issuer's common stock which represented a payment-in-kind dividend on 5,373 shares of the Issuer's convertible preferred stock owned at the time of the dividend payment date.